Clinical Trials Browser

OTHER × Epstein-Barr Virus Infections × avelumab × Clear all

NCT02875613 2024-08-28

Avelumab for Recurrent/Metastatic Nasopharyngeal Cancer

Phase 2 Terminated

6 enrolled 8 charts

Nasopharyngeal Neoplasms, Epstein-Barr Virus Infections